Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer.

被引：0
|
作者：
McArthur, H. L. [1 ]
Rugo, H. [2 ]
Nulsen, B. [1 ]
Traina, T. [1 ]
Patil, S. [1 ]
Zhou, Q. [1 ]
Steingart, R. [1 ]
Dang, C. [1 ]
Park, J. [2 ]
Moasser, M. [2 ]
Melisko, M. [2 ]
Sugarman, S. [1 ]
Norton, L. [1 ]
Hudis, C. [1 ]
Dickler, M. N. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Calif San Francisco, Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：281S / 282S
页数：2
相关论文
共 50 条
  • [31] A phase I-II study of tipifarnib plus weekly paclitaxel (P) followed by dose-dense doxorubicin/cyclophosphamide (AC) in stage IIb-IIIc breast cancer (BC).
    Andreopoulou, Eleni
    Vigoda, Ivette Sara
    Valero, Vicente
    Hershman, Dawn L.
    Raptis, George
    Vahdat, Linda T.
    Han, Hyo S.
    Wright, John Joseph
    Pellegrino, Christine M.
    Alvarez, Ricardo H.
    Fehn, Karen
    Fineberg, Susan
    Sparano, Joseph A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer
    Snider, Jessica N.
    Young, Robyn R.
    Schwartzberg, Lee Steven
    Allen, Jeffrey Warren
    Javed, Yasir Ahmed
    Jahanzeb, Mohammad
    Sachdev, Jasgit C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer.
    Wang, Rui
    Yu, Anthony Francis
    Steingart, Richard
    Patil, Sujata
    Baselga, Jose
    Norton, Larry
    Hudis, Cliff
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Dang, Chau
    Fornier, Monica
    Sugarman, Steven
    Troso-Sandoval, Tiffany
    Lake, Diana
    D'Andrea, Gabriella
    Seidman, Andrew
    Sklarin, Nancy
    Dickler, Maura
    Currie, Violante
    Gilewski, Theresa
    Moynahan, Mary Ellen
    Drullinsky, Pamela
    Robson, Mark
    Wasserheit-Leiblich, Carolyn
    Mills, Nancy
    Steingart, Richard
    Panageas, Katherine
    Norton, Larry
    Hudis, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) : 1216 - 1222
  • [35] Long-term cardiac safety and outcomes of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
    Dang, C. T.
    Morris, P. G.
    Patil, S.
    Chen, C.
    Abbruzzi, A.
    Lehman, R.
    Steingart, R.
    Norton, L.
    Hudis, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer
    Schwartz, J
    Domchek, SM
    Hwang, WT
    Fox, K
    ANNALS OF ONCOLOGY, 2005, 16 (02) : 247 - 252
  • [37] Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
    Julia Foldi
    Andrea Silber
    Emily Reisenbichler
    Kamaljeet Singh
    Neal Fischbach
    Justin Persico
    Kerin Adelson
    Anamika Katoch
    Nina Horowitz
    Donald Lannin
    Anees Chagpar
    Tristen Park
    Michal Marczyk
    Courtney Frederick
    Trisha Burrello
    Eiman Ibrahim
    Tao Qing
    Yalai Bai
    Kim Blenman
    David L. Rimm
    Lajos Pusztai
    npj Breast Cancer, 8
  • [38] NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer
    Swain, Sandra M.
    Tang, Gong
    Geyer, Charles E.
    Rastogi, Priya
    Atkins, James Norman
    Donnellan, Paul P.
    Fehrenbacher, Louis
    Azar, Catherine A.
    Robidoux, Andre
    Polikoff, Jonathan
    Brufsky, Adam
    Biggs, David D.
    Levine, Edward A.
    Zapas, John L.
    Provencher, Louise
    Perez, Edith A.
    Paik, Soonmyung
    Costantino, Joseph P.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Preliminary safety results from a multicenter phase II trial of nanoparticle albumin-bound paclitaxel/cyclophosphamide in early stage breast cancer plus trastuzumab in HER-2+patients (pts)
    Raefsky, E.
    Inhorn, R.
    Lange, M.
    Peacock, N.
    Shastry, M.
    Vazquez, E.
    Priego, V.
    Franco, L.
    Hainsworth, J. D.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] A phase II, single-arm, feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate for the adjuvant treatment of early-stage breast cancer (EBC).
    Traina, Tiffany A.
    Hudis, Clifford
    Lehman, Robert
    Rege, Jessicca
    Wang, Wenquan
    Cox, David
    Seidman, Andrew David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345